

**DEBORAH ARIZA**

**COMPARAÇÃO COMPORTAMENTAL E  
NEUROQUÍMICA ENTRE DIFERENTES MODELOS DE  
PARKINSONISMO EM RATOS**

Curitiba  
2009

# **Livros Grátis**

<http://www.livrosgratis.com.br>

Milhares de livros grátis para download.

**DEBORAH ARIZA**

**COMPARAÇÃO COMPORTAMENTAL E  
NEUROQUÍMICA ENTRE DIFERENTES MODELOS DE  
PARKINSONISMO EM RATOS**

Dissertação apresentada como requisito parcial para a obtenção do título de Mestre em Farmacologia, departamento de Farmacologia, Setor de Ciências Biológicas, Universidade Federal do Paraná.

Orientadora: Prof<sup>a</sup>. Dr<sup>a</sup>. Maria Aparecida B. F. Vital

Curitiba  
2009

***Dedico esse trabalho a meus pais, Jeremias Ariza  
e Maria Aparecida P. F. Ariza***

## AGRADECIMENTOS

A Maria Vital, pelo apoio, dedicação e excepcional paciência no processo de orientação.

A minha família, meus pais e irmão, alicerces na minha vida, pelo amor, carinho, dedicação, compreensão, amizade, educação e incentivo para concluir o trabalho.

Ao meu namorado Daniel pela enorme paciência, compreensão e ajuda que demonstrou sempre com amor.

Aos colegas de laboratório, alunos do professor Dr. Claudio da Cunha, pelo auxílio na metodologia usada no trabalho. Patrícia, Evellyn, Edmar e Lucelia. Obrigada.

Ao Marcelo e Ângela, que mesmo muito ocupados, tiveram paciência e disponibilidade para dar sugestões e esclarecer dúvidas.

À minha amiga Camila, minha parceira de cirurgias e dissecações, formamos uma ótima dupla. E também a Janaína nossa nova parceria.

Thiago e Alexandra, amigos, obrigada por disponibilizarem do tempo, que para vocês também é tão escasso, e acreditarem que poderia dar certo!

Agradeço, a todos os colegas do departamento, meninas da gastro, da tóxico, da cardio (Sandra companheira de feriados prolongados), o pessoal da inflamação, do central, e todos aqueles que ao longo do caminho se fizeram presentes através do apoio, estímulo, motivação, conselhos, sugestões e não menos importante, nos momentos de descontração.

Ao professor Roberto Andreatini pela correção dos relatórios e sugestões que foram muito importantes para a dissertação final.

Ao professor Claudio da Cunha pela gentileza, disponibilidade e interesse no trabalho.

A todos os professores do departamento de Farmacologia pelos ensinamentos e conhecimentos cedidos.

Aos funcionários do departamento e do biotério, essenciais na jornada de trabalho.

Ao apoio financeiro do REUNI (CAPES).

Obrigada a todos aqueles que contribuíram em mais uma etapa da minha história de formação.

## **NOTA EXPLICATIVA**

Esta dissertação é apresentada em formato alternativo – artigo para publicação – de acordo com as normas do Programa de Pós-Graduação em Farmacologia da Universidade Federal do Paraná.

Constando de um artigo abordando os experimentos realizados e a discussão dos resultados, formatado conforme as normas propostas pela revista escolhida.

## RESUMO

O presente trabalho visou investigar o comportamento motor, e os níveis de dopamina (DA) e glutathiona (GSH) em três diferentes modelos de parkinsonismo. Ratos foram infundidos bilateralmente na substância negra com três diferentes toxinas: MPTP, 6-OHDA ou LPS. Para a análise comportamental foi utilizado o teste do campo aberto e os parâmetros freqüências de locomoção e levantar, e tempo de imobilidade foram avaliados. Os níveis de DA estriatal e seus metabólitos foram analisados através de HPLC, e os níveis de GSH na substância negra através de reação colorimétrica. Os animais infundidos com MPTP mostraram diminuição na freqüência de locomoção e de levantar no primeiro dia após a cirurgia, em comparação com grupos controle e sham. Os animais do grupo infundido com 6-OHDA mostraram uma redução em todos os parâmetros motores 1, 3 e 7 dias após a cirurgia. Os animais lesados com LPS não mostraram alterações nos parâmetros motores. A análise neuroquímica mostrou que o grupo infundido com MPTP apresentou uma redução significativa dos níveis de DA estriatal 3 e 7 dias após cirurgia. Os ratos que receberam a 6-OHDA apresentaram um aumento significativo nos níveis de DA no primeiro dia seguido de redução desses níveis no terceiro e sétimo dias. O grupo lesado com LPS exibiu uma diminuição nos níveis de DA no sétimo dia após a cirurgia. Os níveis de GSH mostraram-se reduzidos no grupo MPTP no terceiro dia e no grupo LPS em todos os dias analisados. Os níveis de GSH do grupo 6-OHDA não diferiram do grupo controle. Os modelos induzidos pelas toxinas MPTP e 6-OHDA, mas não LPS, foram capazes de causar alterações motoras conforme o esperado para um bom modelo animal da DP e os três modelos foram capazes de alterar os níveis de DA. Os níveis de GSH foram reduzidos nos modelos MPTP e LPS. Estes dados sugerem que todos os modelos são capazes de mimetizar características da DP, mas cada um com suas particularidades e limitações.

## LISTA DE FIGURAS

<b>Figura 1:</b> Representação esquemática da via nigroestriatal normal (A) e da via nigroestriatal na Doença de Parkinson (B) (Dauer & Przedborski, 2003) .....	02
<b>Figura 2:</b> Esquema das reações e respectivas enzimas envolvidas na formação de espécies reativas de oxigênio e nitrogênio. NOS: NO sintase; SOD: superóxido dismutase; GPx: glutathione peroxidase; Prx: peroxirredoxinas; GR: glutathione reductase; TrxR: thioredoxina reductase; Trx: thioredoxina; GSH: glutathione reduzida; GSSG: glutathione oxidada (dímero) (Barbosa et al., 2006) .....	06
<b>Figura 3:</b> Interação sinérgica de mecanismos envolvidos na morte de neurônios dopaminérgicos na DP (Adaptado de: Esposito <i>et al.</i> , 2007) .....	09



## LISTA DE ABREVIATURAS E SIGLAS

AD - Doença de Alzheimer

ATP - Adenosina tri-fosfato

Ca<sup>++</sup> - Cálcio

COX-2 - Ciclooxygenase-2

DA – Dopamina

DNA - Ácido desoxirribonucléico

DOPAC - Ácido dihydroxyphenylacetic

DP – Doença de Parkinson

GPx - Glutathione peroxidase

GR - Glutathione reductase

GSH - Glutathione

GSSG - Glutathione oxidada

HD - Doença de Huntington

H<sub>2</sub>O<sub>2</sub> - Peróxido de hidrogênio

HO<sup>•</sup> - Radical hidroxila

HVA - Ácido Homovanílico

IL - Interleucina

iNOS - Óxido nítrico sintase induzida

LPS - Lipopolissacarídeo

MAO - Monoamina oxidase

MPDP - 1-metil-4-fenil-2,3-dihidropiridinium

MPP<sup>+</sup> - 1-metil-4-fenil-piridinium

MPTP - 1-metil-4-phenyl-1,2,3,6-tetrahidropiridina

NO<sup>•</sup> - Óxido nítrico

NOS - NO sintase

O<sub>2</sub> - Oxigênio

O<sub>2</sub><sup>•-</sup> - Ânion radical superóxido

ONOO<sup>-</sup> - Peroxinitrito

Prx - Peroxirredoxinas

RNS - Espécies reativas de nitrogênio

ROS - Espécies reativas de oxigênio

SN - Substância negra

SNpc - Substância Negra *pars compacta*

SOD - Superóxidos dismutases

TH - Tirosina hidroxilase

TNF-α - Fator de necrose tumoral

Trx - Tiorredoxina

TrxR - Tiorredoxina redutase

VMAT-2 - Transportador vesicular de monoaminas 2

6-OHDA - 6-hydroxydopamine

## SUMÁRIO

	<b>NOTA EXPLICATIVA .....</b>	<b>v</b>
	<b>RESUMO .....</b>	<b>vi</b>
	<b>LISTA DE FIGURAS .....</b>	<b>vii</b>
	<b>LISTA DE ABREVIATURAS E SIGLAS .....</b>	<b>viii</b>
<b>1</b>	<b>INTRODUÇÃO .....</b>	<b>01</b>
<b>2</b>	<b>OBJETIVOS .....</b>	<b>15</b>
	2.1 Objetivos gerais .....	15
	2.2 Objetivos específicos .....	15
<b>3</b>	<b>ARTIGO .....</b>	<b>16</b>
	Abstract .....	17
	Introduction.....	18
	Results .....	20
	Discussion .....	23
	Experimental procedures .....	33
	Animals .....	33
	Drugs .....	33
	Experimental protocol .....	33
	Stereotaxic surgery .....	34
	Open-field .....	34
	Determination of dopamine and metabolites by HPLC-ED .....	35
	Glutathione levels .....	36
	Statistical analysis .....	36
	Acknowledgements .....	37
	References .....	38
	Table and Figure Legends .....	49
	Figure 1: Striatal dopamine levels .....	51
	Figure 2: Glutathione levels in SN .....	52
	Table 1.....	53
	Table 2 .....	54
<b>4</b>	<b>CONCLUSÕES.....</b>	<b>55</b>
	<b>REFERÊNCIAS BIBLIOGRÁFICAS ADICIONAIS .....</b>	<b>56</b>

## 1. INTRODUÇÃO

A Doença de Parkinson (DP) é a segunda mais freqüente doença neurodegenerativa após Doença de Alzheimer (AD) (Przedborski, 2005, Dunnet e Bjorklund, 1999; Dauer e Przedborski, 2003; Emborg, 2004). As manifestações clínicas ou denominados sinais cardinais da DP incluem bradicinesia, tremor de repouso, rigidez, instabilidade postural e anormalidades na marcha. A principal característica neuroquímica e neuropatológica da DP é a perda progressiva de neurônios dopaminérgicos da Substância Negra *pars compacta* (SNpc) associada a inclusões citoplasmáticas denominadas de corpos de Lewy (Hassler, 1938; Hornykiewicz, 1966; Przedborski, 2005; Dauer e Przedborski, 2003; Mattson et al., 2008; Truong et al., 2009; Peng et al., 2009).

A via dopaminérgica nigroestriatal é composta por neurônios dopaminérgicos cujos corpos celulares se localizam na SNpc e projetam seus axônios para o caudado-putâmen, ou corpo estriado (Przedborski, 2005). A redução na densidade neuronal gera uma diminuição na projeção de fibras dopaminérgicas que se projetam para o estriado dorsal (Figura 1) causando redução dos níveis de dopamina (DA) e de seus metabólitos. Também se observa a redução da atividade de enzimas envolvidas na síntese de DA, como a tirosina hidroxilase (TH) e DOPA-descarboxilase (Gerlach e Riederer, 1996; Rubio-Osornio et al., 2009).




Figura 1: Representação esquemática da via nigroestriatal normal (A) e da via nigroestriatal na Doença de Parkinson (B). Retirada de Dauer e Przedborski, 2003.

Os sinais parkinsonianos aparecem quando a morte neuronal ultrapassa o limiar crítico que acarreta a diminuição de 70-80% de DA nos terminais nervosos do estriado (Hornykiewicz, 1975; Meissner et al., 2004; Warraich et al, 2009)

Os corpos de Lewy são inclusões citoplasmáticas eosinofílicas arredondadas, compostas de várias proteínas, como  $\alpha$ -sinucleína, parkina e neurofilamentos. Apresentam um diâmetro aproximadamente de 15  $\mu\text{m}$  e um centro repleto de hialina (Dauer e Przedborski, 2003; Schulz e Falkenburger, 2004). A deposição dessas proteínas pode ser tóxica aos neurônios, visto que essas causariam danos celulares, seqüestrando outras proteínas importantes para a sobrevivência da célula nervosa (Schulz e Falkenburger, 2004, Mattson et al., 2008). Os neurônios alterados pela formação de corpos de Lewy permanecem funcionais durante certo tempo, entretanto, morrem

prematuramente, sendo que neurônios com axônios longos mostram-se mais vulneráveis que neurônios de circuitos locais (Kidd, 2000). Os corpos de Lewy não são achados específicos da DP, são também encontrados em outras doenças como na AD e na Doença de Huntington (HD) (Schulz e Falkenburger, 2004). Segundo Braak et al. (2003), a deposição dos corpúsculos de Lewy na DP parece ocorrer anteriormente ao aparecimento dos sinais e sintomas motores.

Além da perda neuronal dopaminérgica e do aparecimento dos corpos de Lewy, outros sistemas como o noradrenérgico, através da perda de neurônios do *locus coeruleus*, serotonérgico, através da redução de serotonina no Núcleo da Rafe, e do sistema colinérgico, através da redução de acetilcolina nos Núcleos Basais de Meynert, estão relacionados com os achados neuroquímicos e neuropatológicos na DP (Stoof et al., 1999; Schulz e Falkenburger, 2004; Frisina et al., 2009).

A etiologia da DP, parkinsonismo primário ou idiopático, ou ainda chamado de parkinsonismo esporádico, permanece desconhecida (Mattson et al., 2008) o que a diferencia de outras formas de parkinsonismo como o secundário, que pode ser causado por hidrocefalia, hipóxia, infecções, trauma, tumor, por exposição a drogas e parkinsonismo associado a outras doenças neurodegenerativas, como AD e HD (Dauer e Przedborski, 2003; Fahn e Sulzer, 2004). Ainda, há a forma familiar da doença, 5 a 10%, dos casos, na qual se observam ligações entre a ocorrência da doença e mutações de genes (Vila e Przedborski, 2003; Hald e Lotharius, 2005). A DP familiar e a DP esporádica se diferenciam clinicamente e patologicamente, mas ambas apresentam degeneração dopaminérgica (Moore et al., 2005).

A DP idiopática deve ser diferenciada dos demais tipos de manifestações, visto que qualquer processo que danifique as estruturas dos gânglios da base e suas conexões, ou prejudique suas funções, pode ser capaz de induzir a diferentes tipos de parkinsonismo (Ahlskog, 2001).

Um melhor entendimento sobre a etiologia da DP esporádica, que representa a grande maioria dos casos de parkinsonismo, se faz necessária, sendo alvo do presente trabalho.

Nas últimas décadas, estudos clínicos, *pos mortem* e experimentos *in vivo* e *in vitro* com modelos animais, têm possibilitado algum entendimento sobre a patogênese da doença. As hipóteses incluem: defeitos conformacionais nas estruturas de proteínas citoplasmáticas e disfunções mitocondriais com conseqüente aumento do estresse oxidativo, resultando na morte neuronal (Dauer e Przedborski, 2003; Singh e Dikshi, 2007; Reale et al, 2009). Outros fatores considerados são a excitotoxicidade, neuroinflamação e eventos apoptóticos (Singh e Dikshi, 2007; Reale et al, 2009).

A disfunção mitocondrial tem sido amplamente relacionada com a patogênese da DP (Abou-Sleiman et al., 2006; Mattson et al., 2008). Aproximadamente 100% do oxigênio molecular é consumido pela respiração mitocondrial formando como subprodutos espécies oxidantes (Dauer e Przedboski, 2003). Segundo Barbosa et al. (2006), o metabolismo aeróbio apresenta uma série de reações que podem formar espécies reativas de oxigênio (ROS) e nitrogênio (RNS). Elétrons podem vazar da cadeia de transporte de elétrons reduzindo o oxigênio ( $O_2$ ) a ânion radical superóxido ( $O_2^{\cdot-}$ ). O superóxido também pode ser formado pela enzima NADPH oxidase, presente em diversas células. Em níveis elevados, o superóxido pode mobilizar

o ferro da ferritina. A dismutação do  $O_2^{\cdot-}$  catalisada pelas superóxidos dismutases (SOD) produz peróxido de hidrogênio ( $H_2O_2$ ). Níveis elevados de  $H_2O_2$  podem liberar íons de ferro das proteínas do heme. O ferro reduz  $H_2O_2$  a radical hidroxila ( $HO^{\cdot}$ ) (reação de Fenton) e catalisa a formação de  $HO^{\cdot}$  pela reação de Haber-Weiss. O  $HO^{\cdot}$  é o radical mais reativo encontrado *in vivo*. Esse radical é capaz de oxidar carboidratos, lipídios, proteínas e DNA (Barbosa et al., 2006; Schulz e Falkenburger, 2004; Goldstein e Merenyi, 2008).



O  $H_2O_2$  é eliminado pelas enzimas catalase, glutathiona peroxidase e peroxirredoxinas, as quais atuam em conjunto com as SOD (Figura 2).

As peroxirredoxinas (Prx) utilizam a proteína tioredoxina (Trx) como substrato. A tioredoxina redutase (TrxR), converte a tioredoxina oxidada de volta a sua forma reduzida. Por sua vez, o óxido nítrico ( $NO^{\cdot}$ ) é um radical essencial para a vasorregulação e neurotransmissão, formado pela enzima NO sintase (NOS). Em excesso, o  $NO^{\cdot}$  pode inibir o citocromo oxidase, levando ao aumento da saída de elétrons e formação de superóxido. O  $NO^{\cdot}$  pode reagir com  $O_2^{\cdot-}$  formando peroxinitrito ( $ONOO^{-}$ ). A geração de peroxinitrito *in vivo* pode levar à oxidação e nitração de lipídios, DNA e proteínas e conseqüente morte celular (Schulz e Falkenburger 2004; Barbosa et al., 2006; Goldstein e Merenyi, 2008).

A catalase dismuta  $H_2O_2$  à água e oxigênio. A glutathiona peroxidase (GPx) remove  $H_2O_2$  pela oxidação de glutathiona (GSH) ao dímero GSSG. Este



processo é complementado pela enzima glutathiona redutase (GR), a qual recicla GSSG a GSH (Barbosa et al., 2006; Schulz e Falkenburger 2004).

Dessa maneira, a GSH, um antioxidante endógeno, tem um papel importante na proteção das células contra danos causados pelo estresse oxidativo. Segundo Kumar et al. (2008), a redução de GSH em cérebros de pacientes é o primeiro indicador de estresse oxidativo na DP. A depleção de GSH torna as células mais susceptíveis aos efeitos deletérios do estresse oxidativo e da micróglia ativada (Ibi et al., 1999, Chen et al., 2001; Mosley Lee et al., 2006).




Figura 2: Esquema das reações e respectivas enzimas (em azul) envolvidas na formação de espécies reativas de oxigênio e nitrogênio. NOS: NO sintase; SOD: superóxido dismutase; GPx: glutathiona peroxidase; Prx: peroxirredoxinas; GR: glutathiona redutase; TrxR: tiorredoxina redutase; Trx:tiorredoxina; GSH: glutaiona reduzida; GSSG: glutathiona oxidada (dímero). Retirada de Barbosa et al., 2006.

Segundo Schulz e Falkenburger (2004), muitas biomoléculas cruciais para a integridade celular, incluindo lipídios, proteínas e DNA, podem ser danificadas por espécies reativas (ROS e RNS) e desencadear o processo de neurodegeneração.

Além do estresse oxidativo e conseqüente disfunção mitocondrial, diversos estudos têm demonstrado que a inflamação é outro importante mecanismo envolvido no desenvolvimento e progressão da DP (Asanuma et al., 2004; Pieper et al., 2008; Reale et al., 2009). As células da glia e micróglia, a partir de um insulto tóxico, poderiam produzir substâncias nocivas aos neurônios, tais como citocinas pró-inflamatórias, prostaglandinas, ROS e RNS (Fahn e Sulzer, 2004; Tanaka et al., 2006; Pieper et al., 2008)

De acordo com McGeer e McGeer (2004), a ativação microglial pode resultar em aumento da produção de ânions superóxido e, como demonstrado *in vitro*, tal efeito pode contribuir para processos neurotóxicos, incluindo dano às células dopaminérgicas (Hirsch *et al.*, 2005; Pieper et al. 2008).

Corroborando tais evidências, foi encontrado no fluído cerebrospinal de pacientes parkinsonianos aumento do número de células microgliais ativadas, bem como níveis elevados de citocinas, tais como o fator de necrose tumoral (TNF- $\alpha$ ) e interleucinas (IL): IL-1 $\beta$ , IL-2, IL-4, IL-6, dentre outras (Hirsch *et al.*, 2005).

Conforme Emerit et al. (2004), a excitotoxicidade é a principal causa de morte celular, ocorrendo prolongada despolarização do neurônio, aumento na concentração de cálcio intracelular e ativação da morte celular por mecanismos enzimáticos e nucleares (Doble, 1999).

O glutamato é o principal neurotransmissor excitatório no cérebro de mamíferos, responsável por um terço de todas as sinapses no SNC. Sob certas condições, como insuficiência na captação de glutamato ou despolarização prolongada da terminação nervosa, o glutamato pode se acumular na fenda sináptica e desencadear um processo excitotóxico. Concentrações excitotóxicas de glutamato causam a despolarização excessiva do neurônio pós sináptico e, conseqüentemente, distúrbios da homeostasia iônica e energética, ativação de enzimas líticas mediada por cálcio ( $Ca^{++}$ ), geração de radicais livres, lesão mitocondrial podendo levar à lise celular e morte (Barbosa et al., 2006, Rubio-Osornio et al., 2009).

A apoptose é um importante mecanismo celular pelo qual o organismo controla o número de células, o tamanho dos tecidos e a remoção de células, que podem colocar em risco sua homeostasia (Hengartner, 2000, Mattson, et al., 2008; Wang et al., 2009). Sendo assim, o processo de apoptose encontra-se envolvido, além do desenvolvimento normal do cérebro, na perda de neurônios em doenças neurológicas (Becker e Boni, 2004).

Segundo Schulz e Falkemburger (2004), a apoptose tem sido considerada uma via importante para a morte neuronal no cérebro de humanos e parece contribuir para a degeneração dos neurônios dopaminérgicos da SN. Evidências acumuladas através de estudos *in vitro*, *in vivo* e em humanos (*post mortem*), mostram a morte celular por apoptose como um fator etiológico para a DP (Lev et al., 2003; Wang et al., 2009).

Os estudos citados acima nos mostram que ainda há muito a ser esclarecido sobre os mecanismos envolvidos na patologia da DP. O provável seria o envolvimento não apenas de um, mais a participação de vários fatores

na perda neuronal e, conseqüentemente, a interação desses fatores estariam diretamente relacionados a etiologia da DP.

Essa idéia corrobora com Esposito et al. (2007), que cita a degeneração neuronal, não apenas pela ação de um único fator deletério, mas da convergência de diversos fatores patogênicos (Figura 3)




Figura 3. Interação sinérgica de mecanismos envolvidos na morte de neurônios dopaminérgicos na DP (Adaptado de: Esposito *et al.*, 2007).

O tratamento farmacológico da DP é realizado principalmente por drogas que substituem a dopamina, inibidores da dopa descarboxilase de ação periférica, agonistas dopaminérgicos, inibidores da monoamina oxidase (MAO-B), drogas que liberam dopamina, e antagonistas de receptores colinérgicos, destinados a contrabalancear o desequilíbrio neuroquímico provocado principalmente pela degeneração da via nigroestriatal dopaminérgica (Poewe e

Granata, 1996; Kitamura, et al., 2002; Warraich et al, 2009). Apesar de muitas drogas estarem sendo estudadas, a progressão da doença não é ainda bloqueada por nenhum recurso terapêutico disponível e, conforme a doença progride, faz-se necessária a administração de doses cada vez maiores desses fármacos paliativos (Samii, et al., 1998; Dunnet e Björklund, 1999; Kitamura, et al., 2002; Warraich et al, 2009).

Para a investigação de novos recursos terapêuticos eficazes e da fisiopatologia da DP, faz-se necessário o estudo e desenvolvimento de modelos animais que melhor mimetizem a DP. Modelos animais experimentais são ferramentas importantes na ciência médica, permitindo o estudo dos mecanismos patogênicos e ajudando a compreender os princípios terapêuticos no tratamento dos distúrbios funcionais (sintomas) de doenças humanas (Gerlach e Riederer, 1996).

Infelizmente ainda não existe um modelo que pode, por si só representar fidedignamente todos os sinais e sintomas da DP (Mizuno et al., 1996; Dauer e Przedborski, 2003; Schulz e Falkenburger, 2004; Bové et al., 2005; Da Cunha et al., 2008), no entanto, existem características particulares de cada modelo que facilitam a elucidação da fisiopatologia e permitem estudos sobre a eficácia dos recursos terapêuticos utilizados e de novas abordagens a serem testadas. A comparação entre os modelos utilizados é necessária para fornecer uma visão mais abrangente nesses estudos.

Modelos animais baseados em neurotoxinas têm fornecido importantes provas do envolvimento de disfunções mitocondriais e excitotoxicidade em doenças neurodegenerativas. Várias dessas toxinas foram identificadas, mas

as suas contribuições para a doença ainda não são claras (Mattson e Magnus, 2006)

Segundo a Willner (1986), a validade de um modelo animal pode ser avaliada por três conjuntos de critérios: validade preditiva (*"predictive validity"*), que é avaliada com base na sua capacidade de diferenciar entre drogas que são, ou não são, clinicamente eficazes na patologia humana que está sendo estudada; validade analógica ou por semelhança (*"face validity"*), que é avaliada com base nas qualidades comportamentais e farmacológicas cujas semelhanças com o distúrbio humano podem ser demonstradas; e validade teórica ou por homologia (*"construct validity"*), onde os mesmos processos psicobiológicos responsáveis pela etiologia e fisiopatologia dos sintomas clínicos estejam atuando no modelo.

Muitos modelos que causam a morte neuronal na SN são utilizados como ferramentas para o estudo da DP, dentre esses o MPTP (1-metil-4-phenyl-1,2,3,6-tetrahidropiridina), a 6-OHDA (6-hydroxydopamine) e o LPS (Lipopolisacarídeo), os quais foram escolhidos para a realização desse trabalho.

A injeção estriatal de 6-OHDA leva à degeneração, bem como à ativação astrogliar e microglial na via nigroestriatal dopaminérgica, induzindo à geração de ROS que conduzem a degeneração dos neurônios catecolaminérgicos, e podem também danificar a atividade de proteases (Rodrigues et al., 2003; Vercammen et al., 2006). Diferente da toxina MPTP, a 6-OHDA não atravessa a barreira hematoencefálica, e para reproduzir o modelo de parkinsonismo utilizando essa toxina, é necessário que ela seja infundida intracerebral.

Apesar de muito utilizada, a lesão causada pela 6-OHDA difere da verdadeira lesão da DP, e seu mecanismo ainda não está totalmente elucidada (Dauer e Przedborski, 2003).

Segundo Blum et al. (2001), o mecanismo hipotético da toxicidade da 6-OHDA estaria relacionado a morte dos neurônios catecolaminérgicos por três mecanismos principais: geração de ROS por auto-oxidação intra ou extracelular, formação de  $H_2O_2$  pela atividade da MAO ou inibição da cadeia respiratória mitocondrial.

Embora a 6-OHDA seja utilizada como uma neurotoxina seletiva, ela pode causar uma lesão não específica a qualquer tecido cerebral que contenham neurônios catecolaminérgicos (Kondoh et al., 2005).

Animais lesados bilateralmente com 6-OHDA demonstram os sintomas motores parkinsonianos, entretanto, a lesão bilateral não é um modelo comum (Cenci et al., 2002; Ferro et al., 2005; Da Cunha et al., 2008). A 6-OHDA é usualmente injetada unilateralmente, enquanto que o hemisfério intacto funciona como um controle, constituindo um modelo de hemiparkinsonismo, que é caracterizado por um comportamento motor assimétrico após a administração de drogas dopaminérgicas, devido a um desequilíbrio fisiológico entre o lado lesado e não-lesado (Betarbet *et al.*, 2002; Da Cunha et al, 2008).

O MPTP é uma substância lipossolúvel, fato que lhe confere grande capacidade de cruzar a barreira hemato-encefálica, e penetrar nas células gliais e em neurônios serotoninérgicos, e sofrer a ação da MAO-B é oxidada em 1-metil-4-fenil-2,3-dihidropiridinium (MPDP) e em seguida convertida na forma neurotóxica ativa, o  $MPP^+$  (1-metil-4-fenil-piridinium). O  $MPP^+$  é então seletivamente captado pelos neurônios dopaminérgicos, através dos mesmos

mecanismos de recaptação da dopamina, vindo a produzir degeneração dessas células por interferência com o metabolismo oxidativo (Javitch et al., 1985; Dauer e Przedborski, 2003; Mattson et al., 2008; Kumar et al., 2009). O MPP<sup>+</sup>, dentro dos neurônios dopaminérgicos, pode seguir por três vias: (1) Se concentra dentro da mitocôndria, bloqueando o complexo I, e interrompendo a transferência de elétrons para a ubiquinona. Essa perturbação aumenta a produção de ROS e diminui a síntese de ATP (adenosina tri-fosfato), fazendo, então, que ocorra um estresse oxidativo e uma deficiência energética causada pelo MPP<sup>+</sup>. (2) Interage com enzimas citosólicas, principalmente com aquelas carregadas com cargas negativas. (3) Liga-se ao transportador vesicular de monoaminas 2 (VMAT-2), que transloca o MPP<sup>+</sup> para dentro das vesículas, expulsando dessa o neurotransmissor dopamina. O acúmulo de dopamina no citosol pode sofrer autooxidação e produzir ainda mais ROS, como radicais superóxidos (Vila e Przedborski, 2003; Dauer e Przedborski, 2003; Schulz e Falkenburger, 2004; Mattson et al., 2008). Segundo Przedborski (2005), o MPTP causa a morte de neurônios dopaminérgicos através do estresse oxidativo e da deficiência energética, sendo que, esses processos não são os principais responsáveis pela morte neuronal, mas atuariam provocando uma injúria inicial que ativaria vias moleculares, essas sim que levariam à morte dos neurônios (Rubio-Osornio et al, 2009; Kumar et al 2009).

Mais recentemente o LPS, uma endotoxina presente na parede celular de bactérias Gram-negativas, têm sido estudada e também usada para desenvolver uma síndrome parkinsoniana. O modelo utilizando LPS se faz devido essa substância ser um potente estimulante de células imunes e a



infusão intranigral dessa toxina ser capaz de induzir a degeneração dopaminérgica em ratos (Asanuma *et al.*, 2004; Reale *et al.*, 2009).

O LPS induz a expressão de citocinas inflamatórias como: IL-1 $\beta$ , IL-6, IL-12, TNF- $\alpha$  e óxido nítrico sintase induzida (iNOS). Além disso, a ativação microglial causada por LPS pode resultar em *upregulation* da enzima ciclooxigenase-2 (COX-2) e desta forma, aumentar a síntese de prostaglandinas que podem ativar diretamente a caspase-3 ou indiretamente liberar glutamato levando a excitotoxicidade (Hald e Lotharius, 2005).

A administração de LPS em cérebros de roedores têm reproduzido determinadas características da DP, como degeneração progressiva de DA na substância negra e desordens de movimento. Mas sua principal importância é no entendimento da participação das células gliais, especialmente da micróglia, no processo neurodegenerativo da DP (Liu, 2006; Sugama *et al.*, 2008).

Pode-se observar que muitas questões ainda devem ser respondidas para o entendimento da DP, e estudos envolvendo modelos animais são necessários para auxiliar na compreensão dos mecanismos fisiopatológicos da doença e na busca de novas estratégias terapêuticas.

## 2. OBJETIVOS

### 2.1 Objetivo geral:

O objetivo desse trabalho foi estudar as alterações comportamentais e neuroquímicas em diferentes modelos animais de parkinsonismo 1, 3 e 7 dias após infusão das toxinas: MPTP, 6-OHDA e LPS.

### 2.2 Objetivos específicos:

Avaliar comportamento motor de ratos após a infusão de MPTP, 6-OHDA e LPS na SN no primeiro, terceiro e sétimo dia após a cirurgia.

Analisar os níveis de dopamina e seus metabólitos no estriado nos dias 1, 3 e 7 após lesão na SN com as diferentes toxinas.

Verificar a concentração de glutatona na SN de ratos lesados com MPTP, 6-OHDA e LPS, 1, 3 e 7 dias após cirurgia estereotáxica.

3.

**MPTP, 6-OHDA OR LPS: WHAT IS THE BEST MODEL OF  
PARKINSON'S DISEASE?**

Deborah Ariza<sup>1</sup>, Camila G. Moreira<sup>1</sup>, Patrícia A. Dombrowski<sup>1</sup>, Thiago V. Avila<sup>1</sup>,  
Alexandra Allemand<sup>1</sup>, Daniel A. G. B Mendes<sup>1</sup>, Claudio da Cunha<sup>1</sup>, Maria A. B.  
F. Vital<sup>1</sup>

<sup>1</sup>Department of Pharmacology, Federal University of Paraná, Curitiba, PR,  
Brazil;

Text pages: 40

Figures: 2

Tables:2

\* Address correspondence to:

Dr. Maria A. B. F. Vital

Universidade Federal do Paraná

Setor de Ciências Biológicas

Departamento de Farmacologia

Av. Francisco H. dos Santos s/n

CEP: 81.531 – 990

Caixa Postal: 19031

Curitiba – Paraná – Brasil

FAX number: 0055-041-3266 2042

0055-041-3361 1717

E-mail: vital@ufpr.br

## ABSTRACT

Parkinson's disease (PD) is the second most common neurodegenerative disease. The current study investigated the behavior, dopamine (DA) and glutathione (GSH) level changes in three different PD models. Rats were infused bilaterally in the Substantia nigra (SN) with MPTP, 6-OHDA or LPS. The behavior of the animals was observed in an open field 1, 3, and 7 days after the surgery. The striatal levels of DA and its metabolites were measured by HPLC with electrochemical detection. The levels of GSH in SN were also measured. The MPTP and 6-OHDA rats presented a decrease in locomotion and rearing frequencies 1 day after surgery. In addition, the 6-OHDA rats presented a reduction in locomotion and rearing frequencies 1, 3, and 7 days after surgery. The behavior of the LPS rats in the open field did not differ from the control group. Reduced levels of striatal DA was observed 3 and 7 days after surgery in the MPTP rats, 1, 3, and 7 days after surgery in the 6-OHDA rats, and 7 days after surgery in the LPS rats. The nigral levels of GSH were reduced on day 3 after surgery for the MPTP rats, and on days 1, 3 and 7 after surgery for the LPS rats. These data suggest that MPTP and 6-OHDA, but not LPS, were able to cause motor impairment as expected for a good animal model of PD. DA turnover was reduced in the three models studied. GSH nigral levels were reduced in both MPTP and LPS models.

Key words: Parkinson's disease, MPTP, 6-OHDA, LPS, Dopamine, Glutathione, rats

## INTRODUCTION

Research into the pathogenesis of Parkinson's disease (PD) has rapidly advanced with the development of animal models that allow the investigation of new treatments. Animal models are important tools in experimental medical science because they permit the study of pathogenetic mechanisms and help to understand the therapeutic principles of treating the functional disturbances (symptoms) of human diseases (Gerlach and Riederer, 1996). Some of these models are achieved by the use of neurotoxins, in particular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 6-hydroxydopamine (6-OHDA), and recently lipopolysaccharide (LPS) (Castano et al., 1998; Iravani et al., 2002; Lima et al., 2006).

According to Willner (1986), the validity of animal models is evaluated by three sets of criteria: predictive validity (capacity of the model to predict some event of the clinical condition), face validity (phenomenological similarities between the model and the clinical condition) and construct validity (some similarities between the mechanisms underlying animal behavior and psycho- or neurobiological mechanisms underlying the clinical condition). The criterion for face validity is that the model should simulate the etiology, biochemistry, symptomatology and treatment of the clinical condition being modeled.

Motor symptoms (including slowness of motor activity and rigidity) are the major symptoms of PD (Birkmayer and Riederer, 1985). In most of the studies of PD models, a decrease in locomotion and/or rearing was observed following MPTP administration (Sedelis et al., 2001; Perry et al., 2004, 2005; Lima et al., 2006, Reksidler et al. 2007, 2008). 6-OHDA is an animal model of PD that is

used for screening new therapeutic drugs for PD through their capacity to induce turning behaviour (Da Cunha et al., 2008). However, LPS-lesioned rats do not show this feature (Lima et al., 2006). Moreover, impairment in cognitive function and depression were observed both in PD patients and in animal models (Da Cunha et al., 2001; Gervaerd et al., 2001; Skalisz et al., 2002; Perry et al., 2005; Reksidler et al., 2007). The administration of LPS in the brains of rodents have shown certain features of PD, including the progressive degeneration of the SN and disorders of movement, but its main importance is to unravel the role of glial cells, especially of microglia in neurodegenerative disease (Liu, 2006).

Neurochemical parameters in these PD models indicated that MPTP (Da Cunha et al., 2001; Gevaerd et al., 2001; Perry et al., 2004), 6-OHDA (Lindner et al., 1999; Da Cunha et al., 2001; Ferro et al., 2005) and LPS (Castãno et al., 1998; Herrera et al., 2000; Iravani et al., 2002) caused reduction in DA striatal levels besides the reduction of nigral tyrosine-hydroxylase (TH)-positive neurons. In this line, we demonstrated in a comparative study that intranigral injection of LPS, MPTP or 6-OHDA elicited an up-regulation of COX-2 protein in a time dependent manner (1, 3 and 7 days) after the neurotoxin insult. In addition, we observed approximately the same reduction of TH protein content in the SN on these models.

From another point of view, GSH, an essential tripeptide, is an endogenous antioxidant found in all animal cells which reacts with free radicals to protect cells from singlet oxygen, hydroxylradical and superoxide radical damage. GSH depletion is the first indicator of oxidative stress in the progression of PD (Kumar et al. 2008). Nevertheless, depletion of GSH may

render cells more sensitive to toxic effects of oxidative stress and potentiate the toxic effects of reactive microglia (Ibi et al., 1999; Chen et al., 2001; Lee Mosley et al., 2006).

Although each model recapitulates significant neuropathological features of PD representing parts of the same puzzle, combinatorial study of multiple models are warranted to provide a more comprehensive view of PD pathogenesis (Dawson et al., 2002). Unfortunately there is still no model that alone can mimic all the signs and symptoms of the disease, however, there are some features of models that allow the elucidation of the etiology of the disease and also new features in attempt to therapeutic treatment. The objective of the present study was to evaluate a comparative study between MPTP, 6-OHDA and LPS PD models. The comparison mainly focuses the LPS model because it was recently proposed by some authors, while the others are considered well established models. This comparison was based on behavioral effects, striatal DA levels and GSH depletion 1, 3 and 7 days after lesion induced by LPS, MPTP or 6-OHDA.

## **RESULTS**

The open-field data indicated that these models have different patterns of motor changes. Table 1 illustrates the effect of MPTP, 6-OHDA and LPS infusion in the immobility time of the rats. Figures 1 and 2 demonstrate the locomotion and rearing frequencies 1, 3 and 7 days after the stereotaxic surgery. The MPTP group had a decrease in locomotion [ $F(14.92)= 5.11$ ;

$P < 0.01$ ] and rearing frequencies [ $F(5.81) = 3.81$ ;  $P < 0.05$ ] 1 day after surgery in comparison to the control group (Table 1). The 6-OHDA group showed a reduction in all motor parameters: locomotion 1 [ $F(14.92) = 9.85$ ;  $P < 0.001$ ] and 3 days after surgery [ $F(4.18) = 5.42$ ;  $P < 0.01$ ]; rearing 1 [ $F(5.81) = 6.61$ ;  $P < 0.001$ ] and 3 days [ $F(2.61) = 4.09$ ;  $P < 0.05$ ] after surgery as shown in Table 1. Moreover, the rats of this group also exhibited an increase in the immobility time 1 [ $F(8.34) = 7.32$ ;  $P < 0.001$ ] and 3 days after surgery [ $F(3.95) = 4.83$ ;  $P < 0.01$ ] compared to the control group (Table 1). And the LPS group showed no difference in motor parameters when compared to the control group.

In the second experiment, the DA turnover changes induced by these models was evaluated. The neurochemical analysis indicated that DA levels in the MPTP group presented a reduction 3 [ $F(6.91) = 3.64$ ;  $P < 0.05$ ] and 7 days [ $F(17.1) = 6.14$ ;  $P < 0.001$ ] (Figure 1B and 1C) after lesion. In the 6-OHDA lesioned rats (Figure 1A) a significant increase on striatal DA levels on day 1 [ $F(6.02) = 5.56$ ;  $p < 0.01$ ] was observed. However, a reduction in DA content on days 3 [ $F(6.91) = 5.95$ ;  $P < 0.01$ ] and 7 after surgery [ $F(17.1) = 11.0$ ;  $P < 0.001$ ] (Figure 1B and 1C) was observed. There was a decrease in DA levels on the LPS group 7 days after the toxin [ $F(17.1) = 5.11$ ;  $P < 0.01$ ], in comparison to the control group (Figure 1C).

As shown in Table 2, 3,4-dihydroxyphenylacetic acid (DOPAC) striatal levels of the MPTP group did not differ from control rats. The lesion with 6-OHDA caused a decrease of this metabolite on days 3 [ $F(4.46) = 5.08$ ;  $P < 0.01$ ] and 7 [ $F(8.76) = 7.89$ ;  $P < 0.001$ ] after surgery. The LPS group exhibited a decrease in DOPAC levels on day 7 [ $F(8.76) = 4.23$ ;  $P < 0.05$ ]. In addition, there was a significant increase in striatal homovanillic acid (HVA) levels 1 day after



MPTP [ $F(11,0)= 3.84$ ;  $P<0.05$ ], 6-OHDA [ $F(11,0)= 4.98$ ;  $P<0.01$ ] and LPS [ $F(11,0)= 8.17$ ;  $P<0.001$ ] infusion. A reduction in HVA levels 3 days [ $F(5,62)=4.48$ ;  $P<0.01$ ] and 7 days [ $F(5,52)=6.22$ ;  $P<0.001$ ] after surgery was also observed in the 6-OHDA group.

GSH levels in SN were found to be significantly reduced in the MPTP lesioned rats 3 days after lesion [ $F(5,12)=6,12$ ,  $P<0,01$ ], compared to the non-operated group (Figure 2B). In the 6-OHDA lesioned rats there wasn't significant difference in GSH levels when compared to the control group (Figure 2). A significant decrease in GSH levels on days 1 [ $F(3,59)=4,73$ ,  $P<0,05$ ], 3 [ $F(5,12)=4,06$ ,  $P<0,05$ ] and 7 [ $F(5,42)=2,10$ ,  $P<0,01$ ] was observed after lesion with LPS (Figure 2).

## DISCUSSION

The most important finding in this paper is that the GSH striatal levels were reduced in both MPTP and LPS PD models. Surprisingly, the rats of the 6-OHDA group did not show changes in GSH levels.

Our behavioral results showed that the MPTP group exhibited a motor impairment mainly 24 h after surgery. These data corroborate many other studies of our group (Perry et al., 2004; Lima et al., 2006; Reksidler et al., 2007, 2008; Capitelli et al., 2008). However, this feature was more persistent in the 6-OHDA lesioned rats. LPS did not produce motor signs that are representative of a parkinsonian syndrome. Striatal DA turnover indicated that DA levels decreased 3 (MPTP and 6-OHDA) and 7 (MPTP, 6-OHDA and LPS) days after surgery, while striatal DOPAC levels were reduced 3 and 7 days after surgery in the 6-OHDA lesioned rats. In the LPS group there was a significant reduction of DOPAC in the 7<sup>th</sup> day after lesion. HVA levels increased 1 day after lesion in all models and decreased 3 days after surgery in the 6-OHDA group.

Numerous neurochemistry studies have shown that MPTP administration damages the nigrostriatal pathway, causing cell loss in Substantia nigra pars compacta (SNpc) (Heikkila et al, 1984; Sundström et al, 1987; German et al, 1996; Gevaerd et al, 2001) and DA depletion in the neostriatum (Sonsalla and Heikkila, 1986; Sundström et al, 1987; Da Cunha et al, 2001; Perry et al, 2004). Such effects observed in this animal model mimic the neurochemical alterations observed in PD. Moreover, when MPTP was given in a chronic fashion, it induced the formation of Lewy body-like inclusions in surviving SNpc neurons (Fornai et al., 2005).

In a similar study, we demonstrated that 24 h after infusion MPTP caused a reduction of TH content by 37% in the SN and an increase in cyclooxygenase 2 (COX-2) expression observed in the SN, suggesting damage in the nigrostriatal pathway (Lima et al., 2006). In this line, COX-2 expression is induced specifically within SNpc dopaminergic neurons in human postmortem PD specimens and in the MPTP mouse model of PD during the destruction of the nigrostriatal pathway (Teismann et al., 2003).

Neurochemical data indicated that the MPTP-lesioned rats exhibited a decrease in striatal DA levels 3 and 7 days after surgery. DOPAC levels were not changed by this neurotoxin in this time-course analysis. HVA had an increase 24 h after the lesion. These data are in accordance with the literature (Da Cunha et al., 2001; Ferro et al., 2005; Perry et al., 2005).

An important factor for the appearance of motor parkinsonian signs is the extent of striatal DA depletion once it reaches a loss of 80% (Heikkila and Sonsalla, 1992). On the other hand, Vingerhoets, et al. (1994) pointed out that clinical features begin to emerge when there is a 40-60% reduction of nigral neurons and striatal DA. Differences in rat strain, experimental conditions, and MPTP dose might account for the discrepancy. In fact, a chronic low dose of MPTP in monkeys resulted in a decrease of approximately 90% in striatal DA and in its metabolites DOPAC and HVA (Schneider, 1990). Moreover, in C57BL/6 mice that received four injections of MPTP (10 mg/kg) intraperitoneally, the striatal DA concentrations were markedly decreased in 82% three days after the toxin injection as compared with the saline-treated group (Araki et al., 2001). One possible explanation for the discrete reduction observed in the present study may be related to the interval between MPTP

administration and DA detection. Perhaps, this had the influence of a compensatory increase in DA turnover in the remaining dopaminergic neurons. In this sense, of particular interest are the studies of Tanji et al. (1999), who investigated the chronological changes in DA receptors and uptake sites in the striatum and SN of mouse brain. They demonstrated that DA uptake sites had slightly recovered by 21 days. This finding possibly indicates that dopaminergic neurons recover or regenerate in the chronic phase.

The other explanation for the mild DA depletion verified is associated with the incomplete lesion produced by MPTP. In this way, many authors have indicated that, despite the high depletion of DA, the lesion of dopaminergic neurons is partial. In previous studies we demonstrated that bilateral intranigral MPTP produced a 40% reduction in striatal DA compared to control (Gevaerd et al., 2001; Perry et al., 2004) and a 57% decrease in the number of TH immunoreactive neurons in the SN. In the present paper the reduction of DA content was approximately 40% on the third day and 44,88% on the seventh day.

Current data showed that MPTP caused GSH depletion 3 days after surgery indicating an increase in oxidative stress and are in accordance with others from literature (Riederer et al., 1987; Kumar et al., 2008). The GSH deficit in the nigra in PD has been known for at least 20 years. This observation has been independently verified in several groups of research (Jenner et al., 1992; Riederer et al., 1989; Pearce et al., 1997) providing confidence in its validity. Decreased levels of total glutathione (GSH plus GSSG) in autopsied brains from PD patients were first observed by Perry and colleagues (Perry et al., 1982; 1986; Zeevalk et al., 2008). The abundant evidence for oxidative damage

in the SN of PD also attests to an ongoing oxidative stress and it is a reasonable assumption that the low level of GSH in the region contributes to this phenomenon (Zeevalk et al., 2008).

This suggests that the MPTP rat model showed good face and predictive validity. On the other hand, nowadays, this model is sometimes considered inadequate because of the discrepancies caused by differences in strain, administration schedule and regimen of administration. This is considered its principal drawback, mainly when compared to the primate and mouse model of PD. Thus, the MPTP-lesioned rat seems to be a good model of early stage PD since the neurotransmitter depletion was specific for DA and spared the mesohippocampal neurons and also because the SNpc lesion and the consequent DA depletion barely reached the low striatal levels of about 40-60% observed in early stage PD patients, when the first motor symptoms begin to emerge (Obeso et al., 2000; Da Cunha et al., 2001).

The 6-OHDA is another neurotoxin able to induce nigrostriatal regional degeneration when infused in rodents, in a topographic standard very similar to idiopathic PD, but the injury differs from the real injury of the PD, and its mechanism is unclear (Rodriguez et al., 2001; Dauer and Przedborski, 2003). 6-OHDA is an animal model of PD that is used to screen new therapeutic drugs for PD through their capacity to induce rotational behaviour. These results indicate that the infusion of 6-OHDA caused severe damage, indicated by the decrease in the frequencies of locomotion and rearing.

It was verified in this study, that 6-OHDA rats presented an increase in the immobility time 1 and 3 days after surgery. Moreover, the locomotion and rearing frequencies were also reduced in the rats of this group 1 and 3 days

after lesion. Taken together, these results indicate a motor impairment that is directly correlated to the hypokinesia observed in PD patients. Thus, these data are in accordance with a previous study conducted by Lima et al. (2006).

In the brain, 6-OHDA is associated with loss of functions and behaviors related to catecholaminergic activity (Andén et al., 1964; Breese and Taylor, 1970; Ungerstedt, 1971). Administered unilaterally into the nigrostriatal pathway, the lesion leads to restricted ipsilateral damage and the animals do not present deficits in ingestive behaviors (Ungerstedt, 1971).

The lesion of the nigrostriatal pathway by 6-OHDA causes a motor asymmetry that results in robust and dose-dependent contralateral turning behavior when these animals are challenged with DA receptor agonists, like apomorphine (Ungerstedt, 1968; Ungerstedt and Arbuthnott; 1970; Hefti et al., 1980; Przedborski et al., 1995; Deumens et al., 2002). The ipsilateral rotation occurs when indirect DA agonists produce a DA imbalance through activation of the intact nigrostriatal terminal. Contralateral turning behavior induced by direct DA agonists is due to a stimulation of the supersensitive DA receptors localized in the lesioned nigrostriatal terminals when most dopaminergic SNpc neurons have been destroyed (Hefti et al., 1980; Deumens et al., 2002).

Neurochemical results showed that DA and HVA striatal levels increased 24 h after surgery and after that they were reduced 3 and 7 days after the 6-OHDA infusion. In this line, DOPAC levels were reduced 3 and 7 days after lesion. These data corroborate others from the literature (Da Cunha et al., 2001; Ferro et al., 2005). Lindner et al. (1999) demonstrated that young (2 months old) and middle-aged rats (12 months old) that received bilateral striatal infusions of 6-OHDA exhibited a DA depletion of 53 and 77%, respectively.

As reported previously (Da Cunha et al., 2008; Tanaka et al., 1999; Schwarting and Huston, 1996; Ungerstedt, 1968), the infusion of 6-OHDA into the rat medial forebrain bundle, caused an almost complete depletion of DA and its metabolites in the ipsilateral striatum. However, differences in the experimental schedule of dose, route and place of 6-OHDA infusion may contribute to small or moderate lesions (20-40%) (Przedborski et al., 1995; Kirik et al., 1998; Blandini et al., 2007).

Cytotoxicity of 6-OHDA is due to its pro-oxidant activity; the toxin undergoes rapid auto-oxidation in the extracellular space, thus promoting a high rate of reactive oxygen species formation (Hanrott et al., 2006; Blandini et al., 2007). The 6-OHDA leads to the generation of reactive oxygen species (ROS) leading to degeneration of catecholaminergic neurons, but can also damage the activity of protease (Vercammen et al., 2006). The elevation of ROS production by 6-OHDA was less than that by H<sub>2</sub>O<sub>2</sub>. Although the precise mechanism of 6-OHDA-mediated cell death has not been clarified, our previous study demonstrated that its cytotoxicity is mediated by its oxidized product, *p*-quinone in SH-SY5Y cells (Izumi, et al., 2005). Interestingly, the current data indicated that nigral GSH from 6-OHDA-lesioned rats did not differ from control groups.

Thus, this model is valuable as a model of an end stage of PD (Deumens et al., 2002) and also for testing new drugs and therapeutic strategies to minimize this neurodegenerative syndrome; therefore this model also presents a good face and predictive validity.

For the last years, neuroinflammation is believed to be involved in the pathogenesis of PD (Gebicke-Haerter, 2001). Epidemiological studies suggest

that inflammation increases the risk of the development of a neurodegenerative condition such as Alzheimer's disease and PD (Wyss-Coray and Mucke, 2000).

LPS, a highly conserved cell wall component in gram-negative bacteria, can initiate a signaling cascade that induces the expression of inflammatory genes, including those that encode cytokines such as interleukin (IL)-1 $\beta$ , IL-6, and TNF- $\alpha$  (Anisman et al, 2008). It has been reported that several enzymes, including COX and nitric oxide synthase, which are induced during LPS-induced inflammation, contribute to tissue injuries and cell death induced by LPS (Togbe et al, 2007; Giulian et al., 1996). In this line, the damage to the dopaminergic neurons in the SN was permanent, as observed 1 year after LPS injection (Herrera et al., 2000).

In the current study, LPS-lesioned rats did not exhibit motor impairment when they were observed in an open-field. On the other hand, DA and DOPAC striatal levels were reduced 7 days after surgery. HVA striatal levels increased 24 h after the toxin infusion. Otherwise, in the present data, LPS caused an increase in DA levels 3 days after surgery, which could be viewed as a compensatory reaction of dopaminergic neurons that survived the lesion. Thus, Lima et al., (2006) demonstrated an LPS induced reduction of TH protein content in the SN, but not in the striatum, which can indicate an impairment of DA production and, consequently, their transmission.

Several studies have shown that nigral LPS injection results in the reduction of DA and its metabolites besides the reduction of nigral TH-positive neurons (Castãno et al., 1998; Herrera et al., 2000; Iravani et al., 2002). DA neurons were sensitive to LPS *in vivo* and this sensitivity occurs exclusively when LPS is injected into the SN (Castãno et al., 1998).



Microglial activation can be triggered by pathogenically-modified activation of central nervous system proteins, antigens from infection agents such as LPS, prion proteins, or by a complex combination of molecules including ATP, cAMP, IL-1 $\beta$ , IL-6, and IL-10 (Hanisch, 2002; Nakamura, 2002). There is an increase in reactive microglia in the striatum and SN of patients with idiopathic PD (McGeer et al., 1988; Mirza et al., 2000). In postmortem investigations of humans exposed to MPTP, activated microglia have been detected 16 years after the last drug exposure (Langston et al., 1999). Activated microglia and dopaminergic cell loss were also found in the SN of primates years after they were treated with MPTP (McGeer et al., 2003). Moreover, a transient microglial reaction was verified from the 1<sup>st</sup> until the 14<sup>th</sup> day in the SN and striatum of mice that had received intraperitoneal MPTP injection (Kohutnicka et al., 1998). These findings suggest that microglia plays an active role in the pathology of PD and it may indeed perpetuate the degeneration of dopaminergic neurons once activated (Hald and Lotharius, 2005). Thus, the brain area that encompasses the SN has the highest density of microglia (Kim et al., 2000).

From another point of view, the decrease in GSH levels may be a particularly important component of the cascade of events leading to cell death because it occurs in the presymptomatic stage of PD and may directly induce nigral cell degeneration or render neurons susceptible to the actions of toxins (Jenner and Olanow, 1998).

PD patients show a marked depletion of an approximately 40% nigral GSH depletion (Perry et al., 1982). The reduction in nigral GSH content in PD reflects impairment of a major defense system against oxidative stress. It

emphasizes the potential importance of GSH in the pathogenesis of PD (Pearce et al., 1997). Our data presented in Figure 2 indicates that nigral GSH depletion was observed in LPS-lesioned rats 1, 3 and 7 days after surgery. This result corroborates others from literature. In this way, Tyagi et al. (2008) showed that LPS produced an increase in proinflammatory cytokines, malondialdehyde and a decrease in GSH level 24 h in rat brain.

The mechanism responsible for GSH depletion in the nigra is not known (Zeevalk et al., 2008). Since animals prenatally exposed to LPS had higher levels of TNF- $\alpha$ , increased numbers of activated microglia, and a lower ratio of GSH/GSSG relative to controls at baseline, it is possible that this pre-existing neuroinflammation altered the second inflammatory response in such a way that it produced progressive DA neuron loss (Ling et al., 2006).

Taken together, the data suggesting that the infusion of MPTP into the SNpc can be considered an adequate animal model in the investigation of the impairment of motor activity, DA turnover reduction and GSH depletion associated with PD and may mimic the early stage of PD patients. According to the literature data, 6-OHDA infusion is valuable as a model of an end stage of PD and also for testing new drugs. The current paper demonstrated that this toxin also reproduced some motor signs and reduction of DA levels as expected for a PD model. Surprisingly, 6-OHDA did not change striatal GSH levels. Finally, LPS infusion did not cause motor impairment in rats but reduced DA striatal and GSH nigral levels.

In conclusion, the available animal models of PD have contributed to our better comprehension about the pathophysiology and new therapeutic strategies. These data suggest that all models are able to mimic features of PD,

but each with its merits and limitations. However, the current data indicated that MPTP model was the best animal model because it mimics all the behavioral and neurochemical parameters as expected from a good animal model of PD.

## **Experimental procedures**

### **Animals**

Male Wistar rats from our breeding colony weighing 280–320 g at the beginning of the experiments were used. The animals were randomly housed in groups of six in polypropylene cages with wood shavings as bedding and maintained in a temperature-controlled room ( $22\pm 2$  °C) on a 12-h light-dark cycle (lights on at 7:00 a.m.). The animals had free access to water and food throughout the experiment. The studies were carried out in accordance with the guidelines of the Committee on the Care and Use of Laboratory Animals, United States National Institutes of Health. In addition, the protocol complies with the recommendations of Universidade Federal do Paraná and was approved by the University Ethics Committee (Number 0145).

### **Drugs**

The animals were anesthetized with equitiesin (0.3 ml/kg). MPTP–HCl (100 µg in 1 µL of saline; Sigma, St. Louis, MO, USA), 6-OHDA (6 µg in 2 µL of artificial cerebrospinal fluid, a CSF, supplemented with 0.2% ascorbic acid; Sigma) and LPS (2 µg in 1 µL of saline; from *Escherichia coli*, serotype 0111:B4; Sigma) were bilaterally administered.

### **Experimental protocols**

In the first study, to evaluate motor behavior in the open field test, 48 animals were used, divided in 5 groups ( $n=8-11$ /group). Control or non operated animals, sham operated animals, MPTP-injected group, 6-OHDA-injected

group, and LPS-injected group. Locomotion frequency, latency to start the movement, rearing frequency, and immobility were evaluated. This procedure was performed 1, 3 and 7 days after the stereotaxic surgery.

The neurochemical investigation by HPLC-ED evaluated levels of striatal DA and its metabolites. Nigral GSH levels were also measured: Wistar rats (n= 6-9/group), control or non operated animals, sham operated animals, MPTP-injected group, 6-OHDA-injected group, and LPS-injected group. The striatum and the SN of the two hemispheres were dissected from the anterior part and mid brain of the same brains.

### **Stereotaxic surgery**

The animals were anesthetized (intraperitoneal - i.p.) and were bilaterally administered through a 30-gauge stainless steel needle at a rate of 0.33  $\mu\text{L}/\text{min}$ , for 3 min, according to the following coordinates adapted from the atlas of Paxinos and Watson (1986): anteroposterior (AP): -5.0 mm from the bregma; mediolateral (ML):  $\pm 2.1$  mm from the midline; dorsoventral (DV): 8.0 mm from the skull. Animals from the sham groups were submitted to the same general procedure but did not receive MPTP, 6-OHDA, or LPS infusion, and control animals were not operated upon. After surgery, the animals were left in a temperature-controlled chamber until they recovered from anesthesia.

### **Open-field**

To determine behavioral alterations within these three models of Parkinson's disease, we resorted to the open-field as a test of general activity. The apparatus consisted of a rectangular box (40 $\times$ 50 $\times$ 63 cm) whose floor was

divided into 20 (10×10) small rectangles. The animals were gently placed in the right corner of the open field and were allowed to freely explore the area for 5 min. The frequency of locomotion (number of crossings from one rectangle to the other) and rearing (number of times the animals stood on their hind paws) were determined. Hand-operated counters were used to score immobility time (number of seconds of lack of movement during testing). The open field was washed with a 5% water–alcohol solution before behavioral testing to eliminate possible bias due to odors left by previous rats.

#### **Determination of dopamine and metabolites by HPLC-ED.**

The endogenous levels of DA and its non-conjugated metabolites DOPAC and HVA were assayed by reverse-phase HPLC with electrochemical detection (ED). The system consisted of a Synergi Fusion-RP C-18 reverse-phase column (150 x 4.6 mm i.d., 4 µm particle size) fitted with a 4 x 3.0 mm pre-column (SecurityGuard Cartridges Fusion-RP); an electrochemical detector (ESA Coulochem III Electrochemical Detector) equipped with a guard cell (ESA 5020) with the electrode set at 350 mV and a dual electrode analytical cell (ESA 5011A); a LC-20AT pump (Shimadzu) equipped with a manual Rheodyne 7725 injector with a 20µl loop. The column was maintained inside a temperature-controlled oven (25°C - Shimadzu). The cell contains two chambers in series: each chamber includes a porous graphite coulometric electrode, a double counter electrode and a double reference electrode. Oxidizing potentials were set at 100 mV for the first electrode and at 450 mV for the second electrode. DA and metabolites were detected at the second electrode. The tissue samples were homogenized with an ultrasonic cell

disrupter (Sonics) in 0.1 M perchloric acid containing sodium metabisulfite 0.02% and internal standard. After centrifugation at 10.000 G for 30 min, 4°C, 20 µl of the supernatant was injected into the chromatograph. The mobile phase, used at a flow rate of 1 ml/min, had the following composition: 20 g citric acid monohydrated (Merck), 200 mg octane-1-sulfonic acid sodium salt (Merck), 40 mg ethylenediaminetetraacetic acid (EDTA) (Sigma), 900 ml HPLC-grade water. The pH of the buffer running solution was adjusted to 4.0 then filtered through a 0.45 µm filter. Methanol (Merck) was added to give a final composition of 10% methanol (v/v). The peak areas of the external standards were used to quantify the sample peaks.

### **Glutathione levels**

Briefly , a 1:6 dilution of tissue with phosphate buffer 0,1M (pH 6,5) was made and 0.5 ml of the homogenate was mixed with 12,5% trichloroacetic acid (0.5 ml) and kept in ice for 30 min for precipitation of protein. The supernatant was separated by centrifugation at 10,000rpm for 10min at 4 °C. Then, 50µl of the clear supernatant was mixed with 250µl of 0,1M phosphate buffer (pH 8,0) and 5µl of 5,5`- dithiobis-(2-nitrobenzoic acid) in Methanol. The reaction mixture was then incubated for 10min at 37 °C followed by measurement of absorbance at 412 nm in microplate reader using reduced GSH as an external standard.

### **Statistical analysis**

Differences between groups were analyzed by one-way analysis of variance (ANOVA) with repeated measures (trials), followed by the Newman-Keuls test, with the level of significance set at  $P < 0.05$ .

## **ACKNOWLEDGMENTS**

This work was supported by CNPq and CAPES. Maria A. B. F. Vital and Claudio da Cunha are recipients of CNPq fellowships. The authors wish to express their sincere gratitude to PhD Aleksander R. Zamprônio for providing LPS and would like to thank Evellyn Wietzikoski and Edmar Miyoshi for their help in sample preparations and encouragement throughout this study.



## REFERENCES

- Anisman, H., Merali, Z., Hayley, S., 2008. Neurotransmitter, peptides and cytokine processes in relation to depressive disorder: comorbidity between depression and neurodegenerative disorders. *Prog Neurobiol* 85, 1-74.
- Araki, T., Mikami, T., Tanji, H., Matsubara, M., Imai, Y., Mizugak, M., Itoyama, Y., 2001. Biochemical and immunohistological changes in the brain of 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mouse. *European Journal of Pharmaceutical Sciences* 12, 231–238
- Birkmayer W., Riederer, P., 1985. Biological aspects of depression in Parkinson's disease. *Psychopathology* 19, 58-61.
- Blandini, F., Levandis, G., Bazzini, E., Nappi, G., Armentero, M., 2007. Time-course of nigrostriatal, basal ganglia metabolic changes and behavioral alterations following intrastriatal injection of 6-hydroxydopamine in rat: new clues from an old model. *European Journal of Neuroscience* 25, 397-405.
- Breese, G.R., Traylor, T.D., 1970. Effect of 6-hydroxydopamine on brain norepinephrine and dopamine evidence for selective degeneration of catecholamine neurons. *J. Pharmacol. Exp. Ther* 174, 413–420.
- Birkmayer, W., Riederer, P., 1985. *Die Parkinson-Krankheit. Biochemie, Klinik. Therapie.* 2. Auflage. Springer-Verlag, Vienna
- Castaño, A., Herrera, A.J., Cano, J., Machado, A., 1998. Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. *J. Neurochem.* 70, 1584–1592.

- Capitelli, C., Sereniki, A., Lima, M.M.S., Reksidler, A.B., Tufik, S., Vital, M.A.B.F., 2008. Melatonin attenuates tyrosine hydroxylase loss and hypolocomotion in MPTP-lesioned rats. *European Journal of Pharmacology* 594, 01-108.
- Chen, Y., Vartiainen, N.E., Ying, W., Chan, P.H., Koistinaho, J., Swanson, R.A., 2001. Astrocytes protect neurons from nitric oxide toxicity by a glutathione-dependent mechanism. *J Neurochem* 77,1601–10.
- Da Cunha, C., Gevaerd, M.S., Vital M.A.B.F., Miyoshi, E., Andreatini, R., Silveira, R., Takahashi, R.N., Canteras, N.S., 2001. Memory disruption in rats with nigral lesions induced by MPTP: a model for early Parkinson's disease amnesia. *Behav Brain Res* 124, 9-18.
- Da Cunha, C., Wietzikoski, E., Ferro, M., Martinez, G., Vital, M., Hipolide, D., Tufik, S., Canteras, N., 2008. Hemiparkinsonian rats rotate toward the side with the weaker dopaminergic neurotransmission. *Behav Brain Res* 189, 364-372.
- Dauer, W., Przedborski, S., 2003. Parkinson's disease: Mechanisms and models. *Neuron* 39, 889-909.
- Dunnet, S.B, Björklund A., 1999. Prospects for new restorative and neuroprotective treatments in Parkinson's disease. *Nat* 399, A32-A39.
- Dawson, T.M., Mandir, A.S., Lee, M.K., 2002. Animal models of PD: pieces of the same puzzle? *Neuron* 35, 219–222.
- Deumens, R., Blokland, A., Prickaerts, J., 2002. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. *Experimental Neurology* 175, 303-317.
- Emborg, M.E., 2004. Evaluation of animal models of Parkinson's disease for neuroprotective strategies. *J. Neurosci. Methods* 139, 121-143.

- Ferro, M.M., Bellissimo, M.I., Anselmo-Franci, J.A., Angellucci, M.E.M., Canteras, N.S., Da Cunha, C., 2005. Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations. *J. Neurosci. Methods* 148, 78–87.
- Fornai, F., Schlüter, O.M., Lenzi, P., Gesi, M., Ruffoli, R., Ferrucci, M., Lazzeri, G., Busceti, C.L., Pontarelli, F., Battaglia, G., Pellegrini, A., Nicoletti, F., Ruggieri, S., Paperelli, A., Sudhof, T.C., 2005. Parkinson-like syndrome induced by continuous MPTP infusion: Convergent roles of the ubiquitin-proteasome system and  $\alpha$ -synuclein. *Proc Nat Acad Sci U S A*, 102, 3413-3418.
- Gebicke-Haerter, 2001. Microglia in neurodegeneration: molecular aspects. *Microsc. Res. Tech.* 54(1), 47-58.
- Gerlach, M., Riederer, P., 1996. Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. *J Neural Transmission* 103, 987-1041.
- German, D.C., Nelson, E.L., Liang, C.L., Speciale, S.G., Sinton, C.M., Sonsalla, P.K., 1996. The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse. *Neurodegeneration* 5, 299-312.
- Gevaerd, M.S., Miyoshi, E., Silveira, R., Canteras, N.S., Takahashi, R.N., Da Cunha, C., 2001. L-DOPA restores striatal dopamine level but fails to reverse MPTP-induced memory deficits in rats. *Int J Neuropsychopharmacol* 4, 361–370.

- Giulian, D., Corpuz, M., Richmond, B., Wendt, E., Hall, E.R., 1996. Activated microglia are the principal glial source of thromboxane in the central nervous system. *Neurochem. Int.* 29, 65-76.
- Hald, A., Lotharius, J., 2005. Oxidative stress and inflammation in Parkinson's disease: Is there a causal link?. *Experimental Neurology* 193, 279-290.
- Hanisch, U.K., 2002. Microglia as a source and target of cytokines. *Glia* 40, 140-155.
- Hanrott, K., Gudmunsen, L., O'Neill, M.J., Wonnacott, S., 2006. 6-Hydroxydopamine-induced apoptosis is mediated via extracellular autooxidation and caspase 3-dependent activation of protein kinase Cdelta. *J. Biol. Chem.*, 281, 5373–5382.
- Hassler, R., 1938. Pathologie der Paralysis Agitans und des postenzephalitischen Parkinsonismus. *J Psychol Neurol* 48, 387-476.
- Hefti, F., Melamed, E., Sahakian, B.J., Wurtman, R.J., 1980. Circling behavior in rats with partial, unilateral nigro-striatal lesions: effect of amphetamine, apomorphine, and DOPA. *Pharmacol. Biochem. Behav.*, 12, 185–188.
- Heikkila, R.E., Hess, A., Duvoisin, R.C., 1984. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. *Science* 224, 1451-1453.
- Heikkila RE, Sonsalla PK (1992) The MPTP-treated mouse as a model of parkinsonism: how good is it? *Neurochem Int* 20, 299S–303S.
- Herrera, A.J., Castaño, A., Venero, J.L., Cano, J., Machado, A., 2000. The single injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. *Neurobiol. Dis.* 7, 429–447.

- Hornykiewick, O., 1966. Dopamine and brain function. *Pharmacol Rev.* 18, 925-964.
- Ibi, M., Sawada, H., Kume, T., Katsuki, H., Kaneko, S., Shimohama, S., Akaike, A., 1999. Depletion of intracellular glutathione increases susceptibility to nitric oxide in mesencephalic dopaminergic neurons. *J Neurochem* 73, 1696–703.
- Iravani, M.M., Kashefi, K., Mander, P., Rose, S., Jenner, P., 2002. Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. *Neurosci* 110, 49–58.
- Izumi, Y., Sawada, H., Sakka, N., Yamamoto, N., Kume, T., Katsuki, H., Shimohama, S., Akaike, A., 2005. *J. Neurosci. Res.* 79, 849–860.
- Jenner, P., Olanow, C.W., 1998. Understanding cell death in Parkinson's disease. *Ann. Neurol.* 44(3 Suppl 1), S72-84.
- Kim, W.G., Mohny, R.P., Wilson, B., Jeohn, G.H., Liu, B., Hong, J., 2000. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. *J. Neurosci.* 20, 6309-6316.
- Kirik, D., Rosenblad, C., Bjorklund, A., 1998. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. *Exp. Neurol.*, 152, 259–277.
- Kohutnicka, M., Lewandowska, E., Kurkowska, J., Członkowski, A., Członkowska, A., 1998. Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methy-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). *Immunopharmacology* 39, 167–180.

- Kumar, P., Kaundal, R.K., More, S., Sharma, S.S., 2008. Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson's disease. *Behav Brain Res* 197, 398-403.
- Langston, J.W., Forno, L.S., Tetrud, J., Reeves, A.G., Kaplan, J.A., Karluk, D., 1999. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methy-4-phenyl-1,2,3,6-tetrahydropyridine exposure. *Ann. Neurol.* 46, 598–605.
- Lee Mosley, R., Benner, E.J., Kadiu, I., Thomas, M., Boska, M.D., Hasan, K., Laurie, C., Gendelman, H.E., 2006. Neuroinflammation, oxidative stress, and the pathogenesis of Parkinson's disease. *Clin Neurosci Res* 6, 261-281.
- Lindner, M.D., Caln, C.K., Plone, M.A., Frydel, B.R., Blaney, T.J., Emerich, D.F., Hoane, M.R., 1999. Incomplete nigrostriatal dopaminergic cell loss and partial reductions in striatal dopamine produce akinesia, rigidity, tremor and cognitive deficits in middle-aged rats. *Behav Brain Res* 102, 1-16.
- Lima, M.M.S., Braga, A.R., Zanata, S.M., Machado, H.B., Tufik, S., Vital, M.A.B.F., 2006. Different parkinsonism models produce a time-dependent induction of COX-2 in the substantia nigra of rats. *Brain Res* 110, 117-125.
- Ling, Z., Zhu, Y., Tong, C., Snyder, J.A., Lipton, J.W., Carvey, P.M., 2006. Progressive dopamine neuron loss following supra-nigral lipopolysaccharide (LPS) infusion into rats exposed to LPS prenatally. *Experimental Neurology* 199, 499-512.
- Jenner, P., Dexter, D.T., Sian, J., Schapira, A.H.V., Marsden, C.D., 1992. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. *Ann Neurol* 32, S82.

- Liu, B., 2006. Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of parkinson's disease. *The AAPS Journal* 8 (3), E606 – E621.
- McGeer, P.L., Itagaki, S., Boyes, B., McGeer, E.G., 1988. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. *Neurology* 38,1285-1291.
- McGeer, P.L., Scwab, C., Parent, A., Doudet, D., 2003. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine administration. *Ann. Neurol.* 54, 599–604.
- Mirza, B., Hadberg, H., Thomsen, P., Moos, T., 2000. The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease. *Neuroscience* 95, 425–432.
- Miyoshi, E., Wietzikoski, S., Camplessei, M., Silveira, R., Takahashi, R.N., Da Cunha, C., 2002. Impaired learning in a spatial working memory version and in a cued version of the water maze in rats with MPTP-induced nigral lesion. *Brain Res Bull* 58, 41-47.
- Nakamura, Y., 2002. Regulating factors for microglial activation. *Biol. Pharm. Bull.* 25, 945–953.
- Obeso, J.A., Rodriguez-Oroz, M.C., Rodriguez, M., DeLong, M.R., Olanow, C.W., 2000. Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model. *Ann. Neurol.* 47, 22-34.
- Pearce, R.K., Owen, A., Daniel, S., Jenner, P., Marsden., C.D., 1997. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. *J Neural Transm* 104, 661-677.

- Perry, J.C., Da Cunha, C., Anselmo-Franci, J., Andreatini, R., Miyoshi, E., Tufik, S., Vital, M.A.B.F., 2004. Behavioral and neurochemical effects of phosphatidylserine in MPTP lesion of the substantia nigra in rats. *European Journal of Pharmacology* 484, 225-233.
- Perry, J.C., Hipolide, D.C., Tufik, S., Martins, R.D., Cunha, C., Andreatini, R., Vital, M.A.B.F., 2005. Intra-nigral MPTP lesion in rats: behavioral and autoradiography studies. *Experimental Neurology* 195, 322-329.
- Perry, T.L., Godin, DV, Hansen, S., 1982. Parkinson's disease: a disorder due to nigral glutathione deficiency? *Neurosci Lett* 33, 305-310.
- Perry, T.L., Yong, V.W., 1986. Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. *Neurosci Lett* 67, 269-274.
- Przedborski, S., Jackson-Lewis, V., Fahn, S., 1995. Antiparkinsonian therapies and brain mitochondrial complex I activity. *Mov Disord* 10(3), 312-7.
- Przedborski, S., 2005. Pathogenesis of nigral cell death in Parkinson's disease. *Parkinsonism and Related Disorders*. 11, S3-S7.
- Reksidler, A.B., Lima, M.M.S., Zanata, S.M., Machado, H.B., Da Cunha, Andreatini, R., Vital, M.A.B.F., 2007. COX-2 inhibitor Parecoxib produces neuroprotective effects in MPTP-lesioned rats. *European J Pharmacol.* 560, 163-175.
- Reksidler, A.B., Lima, M.M.S, Dombrowski, P., Andersen, M.L., Zanata, S.M., Andreatini, R., Tufik, S., Vital, M.A.B.F., 2008. Repeated intranigral MPTP administration: a new protocol of prolonged locomotor impairment mimicking Parkinson's disease. *J Neurosci Methods*. 167, 268-277.



- Riederer, P., Sofic, E., Rausch, W.D., Schmidt, B., Reynolds, G.P., Jellinger, K., Youdim, M.B.H., 1989. Transition metals, ferritin, glutathione and ascorbic acid in Parkinsonian brains. *J Neurochem* 52, 515.
- Riederer, P., Strolin, B.M., Dostert, P., Sofic, E., Heusch-neider, G., Guffroy, D., 1987. Do glutathione and ascorbic acid play a role in the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine?. *Pharmacol Toxicol* 60(S1), 39.
- Rodriguez, M., Barroso-Chinea, P., Abdala, P., Obeso, J., Gonzalez-Hernandez, T., 2001. Dopamine cell degeneration induced by intraventricular administration of 6-hydroxydopamine in the rat: similarities with cell loss in Parkinson's disease. *Exp. Neurol.* 169, 163-181.
- Schulz, J.B., Falkenburger, B.H., 2004. Neuronal pathology in Parkinson's disease. *Cell and Tissue Research* 318, 135-147.
- Schneider, J.S., Kovelowski, C.J., 1990. Chronic exposure to low doses of MPTP. Cognitive deficits in motor asymptomatic monkeys. *Brain Res.* 519,122–128.
- Schwartz, R.K., Huston, J.P., 1996. The unilateral 6-hydroxydopamine lesion model in behavioral brain research: analysis of functional deficits, recovery and treatments. *Prog Neurobiol* 50, 275–331.
- Sedelis, M., Schwartz, R.K.W., Huston, J.P., 2001. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. *Behav Brain Res* 125, 109-125.
- Skalisz, L.L., Beijamini, V., Joca, S.L., Vital, M.A., Da Cunha, C., Andreatini, R. 2002. Evaluation of the face validity of reserpine administration as an animal model of depression-Parkinson's disease association. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 26, 879–883.

- Sonsalla, P.K., Heikkila, R.E., 1986. The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. *Eur J Pharmacol* 129, 339-345.
- Sundström, E., Strömberg, I., Tsutsumi, T., Olson, I., Jonsson, G., 1987. Studies on the effect of 1-methyl-4 phenyl-1,2,3,6- tetrahydropyridine (MPTP) on central catecholamine neurons in C57BL/6 mice. Comparison with three other strains of mice. *Brain Res.* 405, 26-38.
- Tanji, H., Araki, T., Nagasawa, H., Itoyama, Y., 1999. Differential vulnerability of dopamine receptors in the mouse brain treated with MPTP. *Brain Res.* 824, 224-231.
- Teismann, P., Tieu, K., Choi, D.K., Wu, D.C., 2003. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. *Proc Natl Acad Sci* 100, 5473-5478.
- Togbe, D., Schnyder-Candrian, S., Schnyder, B., Doz, E., Noulin, N., Janot, L., Secher, T., Gasse, P., Lima, C, Coelho, F.R., Vasseur, V., Erard, F., Ryffel, B., Couillin, I., Moser, R., 2007. Toll-like receptor and tumour necrosis factor dependent endotoxin-induced acute lung injury. Review.. *Int J Exp Pathol.* 88(6), 387-91.
- Tyagi, E., Agrawal, R., Nath, C., Shukla, R., 2008. Influence of LPS-induced neuroinflammation on acetylcholinesterase activity in rat brain. *Journal of Neuroimmunology* 205, 51-56.
- Ungerstedt, U., 1968. 6-hydroxydopamine induced degeneration of central monoamine neurons. *Eur J Pharmacol* 5, 107–110

- Ungerstedt, U., Arbuthnott, G.W., 1970. Quantitative recording of rotational behavior in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. *Brain Res* 24, 485–493
- Ungerstedt, U., 1971. Histochemical studies on the effect of intracerebral and intraventricular injections of 6-hydroxydopamine on monoamine neurons in the rat brain. In Malmfors T, Thoenen H (eds), *6-Hydroxydopamine and Catecholamine Neurons*, 101–127.
- Vercammen, L., Der Perren, A.V., Vaudano, E., Gijssbers, R., Debyser, Z., Den Haute, C.V., Baekelandt, V., 2006. Parkin Protects against Neurotoxicity in the 6-Hydroxydopamine Rat Model for Parkinson's Disease. *Molecular Therapy* 14, 716-723.
- Willner, P., 1986. Validation criterion for animal models of human mental disorders: learned helplessness as a paradigm case. *Prog. Neuropsychopharmacol. Biol. Psychiatry*, 10, 677–609.
- Wyss-Coray, T., Mucke, L., 2000. Ibuprofen, inflammation and Alzheimer disease. *Nature Medicine* 6, 973–974.
- Zeevalk, G.D., Razmpour, R., Bernard, L.P., 2008. Glutathione and Parkinson's disease: Is this elephant in the room? *Biomedicine & Pharmacotherapy* 62, 236-249.

## Table legend

Table 1: Locomotion, rearing frequencies, latency to start movement and immobility time of MPTP, 6-OHDA and LPS lesioned rats. The animals were treated with MPTP 100mg/mL, 6-OHDA 6 mg/mL and LPS 2 mg/mL and observed in open-field test 1, 3 and 7 days after the stereotaxic surgery. The values are expressed as mean  $\pm$  SEM ( $n = 8-11$ /group). \*\* $P < 0.01$  and \*\*\* $P < 0,001$  compared to the non-operated group. Results were analyzed by ANOVA followed by the Newman-Keuls test.

Table 2: Striatal DOPAC and HVA levels after MPTP (100mg/mL), 6-OHDA (6mg/mL) or LPS (2mg/mL) analyzed 1, 3 and 7 days after de lesion. Results were analyzed by ANOVA followed by the Newman-Keuls test. Values are expressed as mean  $\pm$  SEM ( $n=6-9$ /group). \* $P < 0,05$ , \*\* $P < 0,01$ , \*\*\* $P < 0,001$  compared to the non-operated group.

## Figure Legends

Figure 1: Striatal dopamine levels 1 day (A), 3 days (B) and 7 days (C) after MPTP (100mg/mL), 6-OHDA (6mg/mL) or LPS (2mg/mL). Values are expressed as mean  $\pm$  SEM ( $n=6-9$ /group). Results were analyzed by ANOVA followed by the Newman-Keuls test. \*\* $P < 0,01$ , \*\* $P < 0,001$  and \*\*\* $P < 0,001$  compared to the non-operated group.

Figure 2: Glutathione levels in SN of MPTP (100mg/mL), 6-OHDA (6mg/mL) or LPS (2mg/mL) lesioned rat levels 1 (A), 3 (B) and 7 days (C) after surgery. Results were analyzed by ANOVA followed by the Newman-Keuls test. Values are expressed as mean  $\pm$  SEM ( $n=6-9$ /group). \* $P<0,05$ , \*\* $P<0,01$ , \*\*\* $P<0,001$  compared to the non-operated group.




Figure 1




Figure 2

**Table 1**

		Day 1	Day 3	Day 7
<b>Locomotion Frequency</b>	Control	85.33±5.17	78.05±6.37	61.05±7.23
	Sham	78.50±8.86	74.70±9.45	51.00±9.05
	MPTP	52.18±8.57**	64.54±7.28	58.63±7.38
	6-OHDA	17.22±6.63***	35.66±9.61**	36.55±11.19
	LPS	81.60±6.54	57.90±8.04	62.70±8.03
<b>Immobility time (s)</b>	Control	13.72±3.90	31.83±6.52	55.17±14.28
	Sham	56.90±29.57	47.90±17.58	45.50±10.80
	MPTP	26.09±11.43	28.91±8.57	39.82±10.28
	6-OHDA	131.22±30.13***	96.33±22.99**	90.33±25.34
	LPS	7.30±2.15	36.90±12.95	37.80±9.95
<b>Rearing Frequency</b>	Control	28.00±2.28	20.94±1.67	19.88±2.90
	Sham	21.20±3.77	19.40±4.13	12.50±2.04
	MPTP	17.90±2.37*	19.90±2.80	15.72±2.64
	6-OHDA	9.33±3.23***	10.55±2.32*	11.55±2.67
	LPS	22.00±2.99	14.90±2.22	16.50±2.15



**Table 2**

	Control	Sham	MPTP	6-OHDA	LPS
Days					
<b>HVA</b>					
1	696.87±30.81	873.82±126.65	1347.94±238.21*	1572.55±193.88**	2082.07±153.41***
3	688.67±48.26	706.91±96.12	581.64±46.27	364.30±83.49**	841.02±89.33
7	766.36±51.96	727.11±70.15	597.79±73.49	351.61±44.39***	577.06±80.92
<b>DOPAC</b>					
1	1630.84±110.68	1827.42±374.93	2188.69±393.08	2940.19±361.64	2256.88±248.46
3	1582.34±158.39	1514.56±194.91	1219.40±120.62	739.98±166.66**	1592.55±187.20
7	1722.90±128.46	1565.17±147.02	1277.78±193.42	576.20±56.87***	1151.28±134.93*

#### 4. CONCLUSÕES

Concluimos através do presente trabalho, que todos os modelos são capazes de mimetizar características da DP, mas cada um com suas particularidades e limitações.

A toxina MPTP foi capaz de provocar alterações motoras como diminuição da frequência de locomoção e levantar 1 dia após a infusão, mimetizando características motoras iniciais da DP. Além disso, foi capaz de promover diminuição nos níveis de DA 3 e 7 dias após infusão, aumento do HVA no primeiro dia, e diminuição da GSH 3 dias após infusão.

A infusão da 6-OHDA causou severo prejuízo motor com diminuição da frequência de locomoção e levantar, além do aumento da imobilidade nos dias 1 e 3 após a cirurgia. Os níveis de DA e seu metabólito HVA mostraram-se aumentados no primeiro dia e ao terceiro e sétimo dia a DA e seus metabólitos, HVA e DOPAC, estavam diminuídos. Surpreendentemente os níveis de GSH não se alteraram em nenhum dos tempos testados.

Não ocorreram alterações na atividade motora dos animais após infusão de LPS. Houve aumento do metabólito HVA no primeiro dia após a lesão e diminuição de DA e DOPAC no sétimo dia. Os níveis de GSH mostraram-se diminuídos em todos os dias testados.

## REFERÊNCIAS BIBLIOGRÁFICAS ADICIONAIS

- Ahlskog, J.E., 2001. Diagnosis and differential diagnosis of Parkinson's disease and parkinsonism. *Parkinsonism and Related Disorders* 7, 63-74.
- Abou-Sleiman, P.M., Muqit, M.M.K., Wood, N.W., 2006. Expanding insights of mitochondrial dysfunction in Parkinson's disease. *Nat Rev Neurosci*, 7, 207-219.
- Asanuma, M. Diaz-Corrales F;J., Miyazaki, I., Ogawa, N., 2004. Quinone formation as dopaminergic neuron-specific oxidative stress in the pathogenesis of sporadic Parkinson's disease and neurotoxin-induced parkinsonism. *Acta Medica Okayama* 58, 221-233.
- Barbosa, L.F., Medeiros, M.H.G., Augusto, O., 2006. Danos oxidativos e neurodegeneração: O quê aprendemos com animais transgênicos e nocautes? *Quimica Nova* 29, 1352-1360.
- Becker, E.B.E., Boni, A., 2004. Cell cycle regulation of neural apoptosis in development and diseases. *Progress in Neurobiology* 72, 1-25.
- Braak, H.; Tredici, K.D.; Rub, U., Bratzke, H., Del Tredici, K., 2003. Staging of brain pathology related to sporadic Parkinson's disease. *Neurobiology of Aging* 24, 197-211.
- Da Cunha, C., Wietzikoski, E.C., Marcelo Machado Ferro, M.M., Martinez, G.R., Vital, M.A.B.F., Hipólido, D., Tufik, S., Canteras, N.S., 2008. Hemiparkinsonian rats rotate toward the side with the weaker dopaminergic neurotransmission. *Behavioural Brain Research* 189, 364–372

- Doble, A., 1999. The role of excitotoxicity in neurodegenerative disease: implications for therapy. *Pharmacology & Therapeutics* . 81(3): 163-221.
- Dunnet, S.B., Björklund, A., 1999. Prospects for new restorative and neuroprotective treatments in Parkinson's disease. *Nat* 399, A32-A39.
- Emerit, J., Edeas, M., Bricaire, F., 2004. Neurodegenerative diseases and oxidative stress. *Biomedicine & Pharmacotherapy* 58(1), 39-46.
- Esposito, E., Di Matteo, V., Benigno, A., Pierucci, M., Crescimanno, G., Di Giovanni, G., 2007. Non-steroidal anti-inflammatory drugs in Parkinson's disease. *Exp Neurol*, 205, 295-312.
- Fahn, S.; Sulzer, D., 2004. Neurodegeneration and neuroprotection in Parkinson disease. *NeuroRX: The journal of the American Society for Experimental NeuroTherapeutics* 1, 139-154.
- Goldstein, S., Merenyi, G., 2008. The chemistry of peroxynitrite: implications for biological activity. *Methods Enzymol.* 436,49–61.
- Hengartner, M. O., 2005. The biochemistry of apoptosis. *Nature* 407: 770-776.
- Hirsch, E.C., Hunot, S., Hartmann, A., 2005. Neuroinflammatory processes in Parkinson's disease. *Parkinsonism and Related Disorders* 11, S9-S15.
- Lev N., Melamed E., Offen D., 2003. Apoptosis and Parkinson's disease. *Prog Neuropsychopharmacol*, 27, 245-250.
- Kitamura, Y., Kakimura, J., Taniguchi, T., 2002. Antiparkinsonian drugs and their neuroprotective effects. *Biological & Pharmaceutical Bulletin* 25(3), 284-90.
- Kumar, P., Kaundal, R.K., More, S., Sharma, S.S., 2009. Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson's disease. *Behavioural Brain Research* 197, 398–403

- Mattson, M. P., Marc Gleichmann, M., Cheng, A., 2008. Mitochondria in Neuroplasticity and Neurological Disorders. *Neuron* 60, 748-766.
- McGeer, P.L.; McGeer, E.G., 2004. Inflammation and Neurodegeneration in Parkinson's disease. *Parkinsonism and Related Disorders* 10: S3-S7.
- Moore, D.J., West, A.B., Dawson, V.L., Dawson, T.M., 2005. Molecular Pathophysiology of Parkinson's disease. *Annual Review of Neuroscience* 28, 57-87.
- Peng, J., Stevenson, F.F., Oo, M.L., Andersen, J.K., 2009. Iron-enhanced paraquat-mediated dopaminergic cell death due to increased oxidative stress as a consequence of microglial activation. *Free Radical Biology & Medicine* 46, 312-320.
- Pieper, H.C., Evert. B.O., Kaut, O., Riederer, P.F., Waha, A., Wüllner, U., 2008. Different methylation of the TNF-alpha promoter in cortex and substantia nigra: Implications for selective neuronal vulnerability. *Neurobiology of Disease* 32, 521-527.
- Poewe, W., Granata, R. Pharmacological treatment of Parkinson's disease. In: Watts, R.L, Koller, W.C., 1996. *Movement disorders. Neurologic principles and practice.* New York, McGraw-Hill, 201-219.
- Reale, M., Iarlori, C., Thomas, A., Gambi, D., Perfetti, B., Di Nicola, M., Onofri, M., 2009. Peripheral cytokines profile in Parkinson's disease. *Brain, Behavior, and Immunity* 23, 55-63.
- Rubio-Osornio, M., Montes, S., Pérez-Severiano F., Aguilera, P., Floriano-Sánchez, E., Monroy-Noyola, A., Ríos, C., 2009. Copper reduces striatal protein nitration and tyrosine hydroxylase inactivation induced by MPP+ in rats. *Neurochemistry International* X, XX-XX

- Samii, A., Nutt, J.G., Ransom, B.R., 2004. Parkinson's disease. *Lancet* 363, 1783-1793.
- Singh, S., Dikshit, M., 2007. Apoptotic neuronal death in Parkinson's disease: Involvement of nitric oxide. *Brain Res Ver* 54, 233 -250, 2007.
- Stoof, J. C.; Winogrodzka, A.; Van Muiswinkel, F.L., Wolters, E.C., Voorn, P., Groenewegen, H.J., Booij, J., Drukarch, B., 1999. Leads for the development of neuroprotective treatment in Parkinson's disease and brain imaging methods for estimating treatment efficacy. *European Journal of Pharmacology* 375, 75-86.
- Truong, L., Allbutt, H.N., Coster, M.J., Kassio, M., Henderson, J.M., 2009. Behavioural effects of a selective NMDA NR1A/2B receptor antagonist in rats with unilateral 6-OHDA+ parafascicular lesions. *Brain Research Bulletin* 78, 91-96.
- Tanaka, S., Ide, M., Shibutani, T., Ohtaki, H., Numazawa, S., Shioda, S., Yoshida, T., 2006. Lipopolysaccharide-induced microglial activation induces learning and memory deficits without neuronal cell death in rats. *J. Neurosci. Res.* 83, 557-566.
- Warraich, S.T., Allbutt, H.N., Billing, R., Radford, J., Coster, M.J., Kassiou, M., Henderson J.M., 2009; Evaluation of behavioural effects of a selective NMDA NR1A/2B receptor antagonist in the unilateral 6-OHDA lesion rat model. *Brain Research Bulletin* 78, 85–90.
- Wang, W., Bu, B., Xie, M., Zhang, M., Yu, Z., Tao, D., 2009. Neural cell cycle dysregulation and central nervous system diseases. *Progress in Neurobiology* X, XX-XX

Vila, M., Przedborski, S., 2003. Targeting programmed cell death in neurodegenerative disease. *Nature Reviews Neuroscience* 4(5), 365-375.

# Livros Grátis

( <http://www.livrosgratis.com.br> )

Milhares de Livros para Download:

[Baixar livros de Administração](#)

[Baixar livros de Agronomia](#)

[Baixar livros de Arquitetura](#)

[Baixar livros de Artes](#)

[Baixar livros de Astronomia](#)

[Baixar livros de Biologia Geral](#)

[Baixar livros de Ciência da Computação](#)

[Baixar livros de Ciência da Informação](#)

[Baixar livros de Ciência Política](#)

[Baixar livros de Ciências da Saúde](#)

[Baixar livros de Comunicação](#)

[Baixar livros do Conselho Nacional de Educação - CNE](#)

[Baixar livros de Defesa civil](#)

[Baixar livros de Direito](#)

[Baixar livros de Direitos humanos](#)

[Baixar livros de Economia](#)

[Baixar livros de Economia Doméstica](#)

[Baixar livros de Educação](#)

[Baixar livros de Educação - Trânsito](#)

[Baixar livros de Educação Física](#)

[Baixar livros de Engenharia Aeroespacial](#)

[Baixar livros de Farmácia](#)

[Baixar livros de Filosofia](#)

[Baixar livros de Física](#)

[Baixar livros de Geociências](#)

[Baixar livros de Geografia](#)

[Baixar livros de História](#)

[Baixar livros de Línguas](#)



[Baixar livros de Literatura](#)  
[Baixar livros de Literatura de Cordel](#)  
[Baixar livros de Literatura Infantil](#)  
[Baixar livros de Matemática](#)  
[Baixar livros de Medicina](#)  
[Baixar livros de Medicina Veterinária](#)  
[Baixar livros de Meio Ambiente](#)  
[Baixar livros de Meteorologia](#)  
[Baixar Monografias e TCC](#)  
[Baixar livros Multidisciplinar](#)  
[Baixar livros de Música](#)  
[Baixar livros de Psicologia](#)  
[Baixar livros de Química](#)  
[Baixar livros de Saúde Coletiva](#)  
[Baixar livros de Serviço Social](#)  
[Baixar livros de Sociologia](#)  
[Baixar livros de Teologia](#)  
[Baixar livros de Trabalho](#)  
[Baixar livros de Turismo](#)